Business & Tech
Waltham Biotech Working on New Use for Alcoholism Drug
See what the drug is being used to treat in a new trial.
The Waltham-based biotech Synchroneuron has started a trial using an alcoholism drug to “lessen the side effects of antipsychotics and other medications,” according to a Boston Business Journal report.
In a new trial, the firm is using the alcoholism drug marketed under the name Campral to treat 90 patients with tardive dyskinesia, “a condition marked by involuntary muscle movements and caused by prolonged use of drugs that block dopamine receptors, including antipsychotic drugs and others used to treat nausea,” according to the report.
Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
We’ve removed the ability to reply as we work to make improvements. Learn more here
